Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study (ARMYDA-AMULET)
Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study - ARMYDA-AMULET
Sponsor: Abbott Medical Devices
A PHASE3 clinical study on Antiplatelet Therapy and Left Atrial Appendage Occlusion, this trial is ongoing. The trial is conducted by Abbott Medical Devices and has accumulated 6 data snapshots since 2021. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Oct 2024 — Sep 2025 [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Nov 2022 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 1 earlier version
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott Medical Devices
- Azienda Ospedaliero Universitaria Maggiore della Carita
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Catania, Italy , Cirié, Italy , Florence, Italy , Milan, Italy , Napoli, Italy , Novara, Italy , Paderno Dugnano, Italy , Parma, Italy , Pavia, Italy , Pisa, Italy and 5 more locations